Xeris Biopharma Holdings Inc (fra:2B30) Share Price

Company Profile

Business description
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Contact
1375 West Fulton Street
Suite 1300
ChicagoIL60607
USA
T: +1 844 445-5704
E: [email protected]
https://www.xerispharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
435

Recommended

SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.

Tom Lauricella | 19 June 2026

Even as competition looks likely to build, the company remains a leading wide-moat business securely at the center of the AI ecosystem.

Brian Colello, CPA | 19 June 2026

Most Australians will end up owning SpaceX — whether they like it or not.

Tyger Fitzpatrick | 19 June 2026

Index	Last price	Change	% Change
All Ordinaries	9,047.30	25.90	-0.29%
CAC 40	8,421.14	46.84	-0.55%
DAX 40	24,985.82	40.98	-0.16%
Dow JONES (US)	51,564.70	72.15	0.14%
FTSE 100	10,363.27	36.43	-0.35%
HKSE	23,924.81	387.35	-1.59%
NASDAQ	26,517.93	496.28	1.91%
Nikkei 225	71,250.06	196.57	0.28%
NZX 50 Index	13,495.63	132.32	0.99%
S&P 500	7,500.58	80.48	1.08%
S&P/ASX 200	8,828.70	27.90	-0.32%
SSE Composite Index	4,090.48	17.59	-0.43%